The United Laboratories

The United Laboratories (TUL) is a leading integrated pharmaceutical company in China, specializing in the research, development, production, and sale of antibiotics, insulin products, and innovative biologics. Founded in 1990 and listed on the Hong Kong Stock Exchange, the company has evolved from a major manufacturer of antibiotic intermediates (such as 6-APA and Amoxicillin) into a powerhouse in the diabetes and metabolic disease space. The company operates a vertically integrated business model with seven major production bases across China, including significant facilities in Zhuhai, Zhongshan, and Inner Mongolia. TUL is currently a major player in the global insulin market and is rapidly expanding its innovative drug pipeline, most notably through its subsidiary, The United Bio-Technology (Hengqin), which focuses on next-generation GLP-1 therapies and triple agonists.